Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review

BACKGROUND: Published data on the relationship between matrix metalloproteinases (MMPs) polymorphisms and ovarian cancer risk have implicated inconclusive results. To evaluate the role of MMPs polymorphisms in ovarian cancer risk, a meta-analysis and systematic review were performed. METHODS: MMPs polymorphisms which could be quantitatively synthesized were involved in meta-analysis. Five comparison models (homozygote model, heterozygote model, dominant model, recessive model, additive model) were carried out, a subgroup analysis was performed to clarify heterogeneity source. The remaining polymorphisms which could not be quantitatively synthesized were involved in systematic review. RESULTS: 10 articles with 20 studies were included in this paper. Among those studies, 8 studies involving MMP1 rs1799750 and MMP3 rs34093618 could be meta-analyzed and 12 studies involving 12 polymorphisms could not. Meta-analysis showed that no associations were found between MMP1 rs1799750 (homozygote model: OR = 0.93, 95%CI = 0.70–1.23, P(OR) = 0.60; heterozygote model: OR = 1.09, 95%CI = 0.78–1.54, P(OR) = 0.61; dominant model: OR = 1.02, 95%CI = 0.83–1.25, P(OR) = 0.84; recessive model: OR = 0.95, 95%CI = 0.75–1.21, P(OR) = 0.67; additive model: OR = 1.00, 95%CI = 0.85–1.17, P(OR) = 0.99), MMP3 rs34093618 (homozygote model: OR = 1.25, 95%CI = 0.70–2.24, P(OR) = 0.46; heterozygote model: OR = 1.08, 95%CI = 0.51–2.31, P(OR) = 0.84; dominant model: OR = 0.97, 95%CI = 0.68–1.38, P(OR) = 0.85; recessive model: OR = 1.12, 95%CI = 0.69–1.80, P(OR) = 0.65; additive model: OR = 1.01, 95%CI = 0.79–1.31, P(OR) = 0.91) and ovarian cancer. Furthermore, similar results were detected in subgroup analysis. The systematic review on 12 polymorphisms suggested that MMP2 C-735T, MMP7 A-181G, MMP8 rs11225395, MMP9 rs6094237, MMP12 rs2276109, MMP20 rs2292730, MMP20 rs12278250, MMP20 rs9787933 might have a potential effect on ovarian cancer risk. CONCLUSIONS: In summary, polymorphisms of MMPs might not be associated with ovarian cancer risk. However, it is necessary to conduct more larger-scale, multicenter, and high-quality studies in the future.